ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

ClinicalTrials.gov ID: NCT03645928

Public ClinicalTrials.gov record NCT03645928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 12:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Study identification

NCT ID
NCT03645928
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Enrollment
245 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Cisplatin Drug
  • Ipilimumab Drug
  • LN-145 Biological
  • LN-145-S1 Biological
  • Lifileucel Biological
  • Nab-Paclitaxel Drug
  • Nivolumab Drug
  • Nivolumab-relatlimab Drug
  • Paclitaxel Drug
  • Pembrolizumab Drug
  • Pemetrexed Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 6, 2019
Primary completion
Aug 8, 2029
Completion
Aug 8, 2029
Last update posted
Jun 18, 2025

2019 – 2029

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
University of California, San Diego La Jolla California 92093 Terminated
University of Southern California Los Angeles California 90007 Active, not recruiting
University of California, Los Angeles Los Angeles California 90095 Active, not recruiting
University of Colorado Denver Colorado 80045 Active, not recruiting
Yale University New Haven Connecticut 06520 Active, not recruiting
Georgetown University Medical Center Washington D.C. District of Columbia 20007 Active, not recruiting
Mount Sinai Medical Center Miami Beach Florida 33140 Withdrawn
Orlando Health Cancer Institute Orlando Florida 32610 Recruiting
Moffitt Cancer Center Tampa Florida 33612 Active, not recruiting
University of Louisville Louisville Kentucky 40292 Recruiting
University of Maryland Baltimore Maryland 21201 Active, not recruiting
Massachusetts General Hospital Boston Massachusetts 02114 Recruiting
Karmanos Cancer Institute Detroit Michigan 48201 Active, not recruiting
Henry Ford Health System Detroit Michigan 48202 Active, not recruiting
MD Anderson at Cooper Camden New Jersey 08103 Recruiting
Morristown Medical Center Morristown New Jersey 07960 Recruiting
Columbia University New York New York 10027 Withdrawn
Memorial Sloan Kettering Cancer Center New York New York 10065 Active, not recruiting
University of Cincinnati Cincinnati Ohio 45219 Terminated
Ohio State University Columbus Ohio 43201 Recruiting
Avera Cancer Institute Sioux Falls South Dakota 57105 Withdrawn
Huntsman Cancer Hospital Salt Lake City Utah 84112 Withdrawn
Fred Hutchinson Cancer Research Center Seattle Washington 98109 Recruiting
Medical College of Wisconsin Milwaukee Wisconsin 53226 Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03645928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 18, 2025 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03645928 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →